Adaptive DBS for PD

Adaptive vs Conventional Deep Brain Stimulation for Parkinson's Disease: A Multi-center Randomized Controlled Trial

The goal of this clinical trial is to evaluate the efficacy and safety of an adaptive deep brain stimulation (aDBS) system for managing Parkinson's disease symptoms. Researchers will compare closed-loop stimulation (which automatically adjusts therapy using real-time brain signals and sleep monitoring) against traditional continuous stimulation (fixed settings) in a randomized, double-blind, crossover study. Participants will undergo surgical implantation of PINS Medical's G1010R neurostimulator, followed by alternating treatment phases where each patient experiences both aDBS and conventional open-loop stimulation modes. Outcomes will assess improvements in without troublesome dyskinesia daily time, motor symptoms (e.g., tremors, rigidity), quality of life, and sleep quality across both therapy periods.

The goal of this clinical trial is to evaluate the efficacy and safety of PINS Medical's rechargeable implantable closed-loop deep brain stimulation (aDBS) system for improving quality of life in Parkinson's disease patients. Researchers will compare adaptive closed-loop stimulation (which automatically adjusts therapy using real-time brain signals) against conventional open-loop stimulation (cDBS) in a prospective, multicenter, double-blind, randomized crossover study. Participants will undergo surgical implantation of the neurostimulator system and progress through five trial phases: screening/surgery, cDBS optimization, aDBS optimization, crossover evaluation, and long-term follow-up across nine visits. During crossover testing, each participant will experience both stimulation modes sequentially while blinded. Key outcomes include duration of troublesome/non-troublesome dyskinesia, "off" time, sleep scales (VAS, PDSS-2, PSQI), motor symptoms (MDS-UPDRS), quality of life (PDQ-39, EQ-5D-5L), and safety parameters. The primary analysis will occur after all randomized subjects complete crossover testing and unblinding (Visit 7).

Inclusion Criteria:

• idiopathic Parkinson's disease

• Hoehn & Yahr (HY) stage 2.5-4 during medication "OFF"

• Subjects must meet one of the following:

  1. Never underwent DBS surgery and suitable for bilateral STN or GPi DBS surgery;
  2. Previous bilateral STN/GPi DBS recipients with only one IPG who:

• Demonstrate responsiveness to conventional cDBS therapy per investigator evaluation,

• Consent to device replacement with G1010R DBS system.

• Willing and physically/mentally able to complete all study visits and procedures

• Capable of comprehending and providing written informed consent

Exclusion Criteria:

• Presence of contraindications to deep brain stimulation (DBS) surgery.
• Beck Depression Inventory-II (BDI-II) score > 25
• Mini-Mental State Examination (MMSE) score < 24 (adjusted for educational level)
• Significant comorbidities that may interfere with DBS therapy per investigator assessment.
• Pre-existing active non-DBS medical implants or metallic cranial implants
• Requirement for diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT) during the study period
• History of ablative neurosurgery or stem cell therapy for Parkinson's disease
• Inability to complete ≥3 consecutive days of comprehensive motor/sleep diaries
• Inability to maintain prescribed medication regimens or comply with protocol requirements
• Current pregnancy, lactation, or planned pregnancy during the study period
• Other conditions deemed by investigators to compromise study suitability
• Participation in other interventional clinical trials within 4 weeks prior to consent